Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
07:00am, Wednesday, 20'th Mar 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics released its 2023 ESG Report, measuring key sustainability focus areas – quality, integrity, accountability, teamwork, and innovation.
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
07:05am, Friday, 01'st Mar 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Mass.
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know
10:56am, Wednesday, 28'th Feb 2024
The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
08:01pm, Tuesday, 20'th Feb 2024
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com
NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript
07:20pm, Tuesday, 20'th Feb 2024
NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
06:36pm, Tuesday, 20'th Feb 2024
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.06 per share a year ago.
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
07:05am, Thursday, 01'st Feb 2024
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has signed the Working with Cancer Pledge to support team members living with or caring for a loved one with cancer.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
07:45pm, Tuesday, 30'th Jan 2024
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
07:05am, Tuesday, 30'th Jan 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
07:20pm, Monday, 22'nd Jan 2024
NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advis
Best Momentum Stocks to Buy for January 9th
11:16am, Tuesday, 09'th Jan 2024
NEO, WIX and LNW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
New Strong Buy Stocks for January 9th
07:31am, Tuesday, 09'th Jan 2024
NEO, WIX, LNW, TM and RBB have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
08:00am, Tuesday, 05'th Dec 2023
FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residua
Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics
10:32pm, Monday, 06'th Nov 2023
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall
NeoGenomics, Inc (NEO) Q3 2023 Earnings Call Transcript
08:03pm, Monday, 06'th Nov 2023
NeoGenomics, Inc (NASDAQ:NEO ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 AM ET Company Participants Kendra Sweeney - VP, IR Chris Smith - CEO Jeff Sherman - CFO Vishal Sikri - President,
